1
|
Duez L, Gkolfakis P, Bastide M, Vuckovic C, Musala C, Van Gossum M, Hoyois A, Mulkay JP, Eisendrath P. Premedication with simethicone for improving the quality of gastric mucosal visualization: a double-blind randomized controlled trial. Endosc Int Open 2022; 10:E1343-E1349. [PMID: 36262507 PMCID: PMC9576330 DOI: 10.1055/a-1922-7773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 07/26/2022] [Indexed: 11/21/2022] Open
Abstract
Background and study aims Saliva, bubbles, or mucus can limit gastric mucosal visualization (GMV), increasing the risk of missed lesions such as gastric cancer. Several studies using endoscopy photodocumentation-based scores have reported increased quality of GMV when mucolytic and/or defoaming agents are administered. This single-center, prospective, double-blind, randomized, placebo-controlled trial aimed to evaluate whether simethicone administration could improve GMV. Patients and methods Patients were randomly assigned (1:1) to receive either 200 mg of simethicone (Group A) or placebo (Group B). Two independent endoscopists reviewed the entire video recording from each examination to assess the quality of GMV. The primary outcome was the rate of adequate GMV, defined as the percentage of patients in each group with a video score scale < 7 based on gastric visualization of five gastric landmarks. Secondary outcomes included procedure duration, patient satisfaction, and side effects. Results A total of 110 consecutive outpatients were randomly assigned to one of the two study groups (11 were excluded for various reasons). For the primary endpoint, 32 patients (61.5 %) in group A achieved adequate GMV compared to one of 47 (2.1 %) in group B (odds ratio [95 % confidence interval]: 73.6 [9.4-576.6]; P < 0.001). Median procedure time did not differ between the groups ( P = 0.55), and no differences were detected in patient satisfaction ( P = 0.18) or side effects ( P = 0.58). No serious adverse events were documented. Conclusions Premedication with simethicone before upper gastrointestinal endoscopy significantly improves the quality of GMV without affecting the duration of the examination, patient satisfaction, and the rate of side effects.
Collapse
Affiliation(s)
- Leo Duez
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Paraskevas Gkolfakis
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Marine Bastide
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Clemence Vuckovic
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Carmen Musala
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Marc Van Gossum
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Alice Hoyois
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Jean-Pierre Mulkay
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| | - Pierre Eisendrath
- Department of Hepato-Gastroenterology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
2
|
Papalavrentios L, Musala C, Gkolfakis P, Devière J, Delhaye M, Arvanitakis M. Multiple stents are not superior to single stent insertion for pain relief in patients with chronic pancreatitis: a retrospective comparative study. Endosc Int Open 2019; 7:E1595-E1604. [PMID: 31788540 PMCID: PMC6877416 DOI: 10.1055/a-1006-2658] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 07/22/2019] [Indexed: 12/19/2022] Open
Abstract
Background and study aims Patients with painful chronic pancreatitis (CP) and distal main pancreatic duct (MPD) stricture are considered candidates for treatment using a single plastic stent insertion. Multiple side-by-side stents have been proposed as an alternative treatment but comparative studies are lacking. The aim of this retrospective study is to assess differences in characteristics and treatment outcomes in patients with CP and MPD strictures treated with a different number of stents during the stenting period. Patients and methods Patients with painful CP and distal MPD obstruction requiring endoscopic treatment (01.2004 - 12.2012) were considered. The study population was divided in three groups: Patients treated with (A) exclusively one stent; (B) one or two stents; and (C) exclusively two stents during the stenting period. Patient characteristics and treatment outcomes were retrospectively assessed. Results Among 284 patients, 85 were selected according to inclusion criteria (Group A: 18, Group B: 35, Group C: 32). Median follow-up duration was 84 months. The median number of endoscopic procedures needed was higher for group B [3 (A) vs. 3 (C) vs. 4 (B), P = 0.001]. Regarding outcome, successful endoscopic treatment was lower in Group C (50 % vs. 88.2 % and 74.2 % for groups A and B, respectively; P = 0.02). This difference was attributed to better clinical outcome in Group A compared to Group C patients [OR(95%CI): 7.50 (1.46 - 38.70); P = 0.04]. Moreover, group C patients experienced higher levels of pain at the end of follow-up period [median Izbicki Score 0 (group A) vs. 0 (group B) vs. 6 (group C), P = 0.03]. Conclusions In patients with painful CP and distal MPD obstruction, treatment with a single stent is associated with better clinical outcome compared to treatment with exclusively two stents during the stenting period.
Collapse
Affiliation(s)
- Lavrentios Papalavrentios
- Erasme University Hospital, Université Libre de Bruxelles, Division of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium
| | - Carmen Musala
- Erasme University Hospital, Université Libre de Bruxelles, Division of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium
| | - Paraskevas Gkolfakis
- Erasme University Hospital, Université Libre de Bruxelles, Division of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium
| | - Jacques Devière
- Erasme University Hospital, Université Libre de Bruxelles, Division of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium
| | - Myriam Delhaye
- Erasme University Hospital, Université Libre de Bruxelles, Division of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium
| | - Marianna Arvanitakis
- Erasme University Hospital, Université Libre de Bruxelles, Division of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium
| |
Collapse
|
3
|
Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, Hartmann D, Bredenoord AJ, Ciriza de Los Rios C, Schubert S, Brückner S, Madisch A, Hayat J, Tack J, Attwood S, Mueller R, Greinwald R, Schoepfer A, Straumann A, Vanuytsel T, Louis H, Musala C, Miehlke S, Frederking D, Bajbouj M, Schlag C, Nennstiel S, Brückner S, Schmelz R, Heimerl S, Stephan AM, Fibbe C, Liedtke (née Laschinsky) N, Keller J, Rosien U, Haag S, Schneider A, Hartmann D, Schmöcker C, Buchholz H, Lammert F, Casper M, Reichert M, Madisch A, Sommer D, Mönnikes H, Stengel M, Schmidtmann M, Müller M, Eckardt A, Wehrmann T, Schubert S, Armerding P, Hofmann WP, Liceni T, von Arnim U, Kandulski A, Weigt J, Börner N, Lutz-Vorderbrügge A, Albert J, Zeuzem S, Blumenstein I, Sprinzl K, Hausmann J, Bredenoord A, Bredenoord A, Warners M, Villarin AL, Arias ÁA, Tejero Bustos MÁ, Carrillo Ramos MJ, Olalla Gallardo JM, Tosina RJ, Molina-Infante J, Zamorano J, Vaquero CS, Francés SC, Pérez T, Rodriguez T, Ciriza de los Ríos C, Rodríguez-Valcárcel FC, Castel de Lucas I, Juan AP, Barenys M, Pons C, Martinez IP, Lauret ME, García AC, Rubio E, Straumann A, Hruz P, Brunner S, Hayat J, Poullis A. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology 2019; 157:74-86.e15. [PMID: 30922997 DOI: 10.1053/j.gastro.2019.03.025] [Citation(s) in RCA: 153] [Impact Index Per Article: 30.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 03/15/2019] [Accepted: 03/18/2019] [Indexed: 12/16/2022]
Abstract
BACKGROUND & AIMS Swallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized for esophageal delivery are sometimes effective, although given off-label. We performed a randomized, placebo-controlled trial to assess the effectiveness and tolerability of a budesonide orodispersible tablet (BOT), which allows the drug to be delivered to the esophagus in adults with active EoE. METHODS We performed a double-blind, parallel study of 88 adults with active EoE in Europe. Patients were randomly assigned to groups that received BOT (1 mg twice daily; n = 59) or placebo (n = 29) for 6 weeks. The primary end point was complete remission, based on clinical and histologic factors, including dysphagia and odynophagia severity ≤2 on a scale of 0-10 on each of the 7 days before the end of the double-blind phase and a peak eosinophil count <5 eosinophils/high power field. Patients who did not achieve complete remission at the end of the 6-week double-blind phase were offered 6 weeks of open-label treatment with BOT (1 mg twice daily). RESULTS At 6 weeks, 58% of patients given BOT were in complete remission compared with no patients given placebo (P < .0001). The secondary end point of histologic remission was achieved by 93% of patients given BOT vs no patients given placebo (P < .0001). After 12 weeks, 85% of patients had achieved remission. Six-week and 12-week BOT administration were safe and well tolerated; 5% of patients who received BOT developed symptomatic, mild candida, which was easily treated with an oral antifungal agent. CONCLUSIONS In a randomized trial of adults with active EoE, we found that budesonide oral tablets were significantly more effective than placebo in inducing clinical and histologic remission. Eudra-CT number 2014-001485-99; ClinicalTrials.gov ID NCT02434029.
Collapse
Affiliation(s)
- Alfredo J Lucendo
- Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain; Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Spain.
| | - Stephan Miehlke
- Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany; Center for Esophageal Diseases, University Hospital Hamburg-Eppendorf, Germany
| | - Christoph Schlag
- II. Medizinische Klinik, Klinikum Rechts der Isar, Technische Universität München, München, Germany
| | - Michael Vieth
- Institute for Pathology, Klinikum Bayreuth, Bayreuth, Germany
| | - Ulrike von Arnim
- Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, Magdeburg, Germany
| | - Javier Molina-Infante
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Spain; Department of Gastroenterology, Hospital Universitario San Pedro de Alcantara, Caceres, Spain
| | - Dirk Hartmann
- Klinik für Innere Medizin I, Sana Klinikum Lichtenberg, Berlin, Germany
| | - Albert Jan Bredenoord
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
| | | | | | - Stefan Brückner
- Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Technische Universität Dresden, Dresden, Germany
| | - Ahmed Madisch
- Department of Gastroenterology, CRH Clinic Siloah, Hannover, Germany
| | - Jamal Hayat
- Department of Gastroenterology, Saint George's University Hospitals National Health Service Trust, London, United Kingdom
| | - Jan Tack
- Department of Gastroenterology, University Hospital, Leuven, Belgium
| | - Stephen Attwood
- Department of Health Services Research, Durham University, Durham, United Kingdom
| | - Ralph Mueller
- Department of Clinical Research and Development, Dr Falk Pharma GmbH, Freiburg, Germany
| | - Roland Greinwald
- Department of Clinical Research and Development, Dr Falk Pharma GmbH, Freiburg, Germany
| | - Alain Schoepfer
- Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Fernandez M, Arvanitakis M, Musala C, Devière J, Van Steenbergen W, Putzeys V, Ausloos F, Bastens B, Gast P, Roeyen G, Berrevoet F, Scheers I, Delhaye M, Deprez PH. The Belgian national registry on chronic pancreatitis: A prospective multi-centre study covering more than 800 patients in one year. Pancreatology 2017; 17:572-579. [PMID: 28600220 DOI: 10.1016/j.pan.2017.05.387] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 05/12/2017] [Accepted: 05/24/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND/OBJECTIVES The epidemiology, natural history, complications, and therapeutic management of chronic pancreatitis (CP) are not well described at the national level. This multi-centre prospective observational study involving eight Belgian hospitals aimed to improve the understanding of these aspects of CP in Belgium. METHODS All patients with a diagnosis of CP based on imaging were eligible for this study. Data were gathered regarding epidemiology, etiology, CP complications, and treatment modalities. RESULTS A total of 809 patients were included between 1/9/2014 and 31/8/2015. Most patients (794) were adults ≥16-years old, 74% were male, the median age at symptom onset was 47 (38-57) years, the median disease duration was 7 (3-13) years, and the median Izbicki pain score (IPS) was 96 (0-195). The main etiological risk factors according to the TIGAR-O classification were alcohol and tobacco (67%). Current drinkers had lower body mass index (BMI) (21.4 kg/m2 vs 24.1 kg/m2), higher IPS (110 vs 56), and longer inability to work than non-drinkers. Current smokers had lower BMI (21.5 kg/m2 vs 25 kg/m2) and higher IPS (120 vs 30) than non-smokers. Endocrine insufficiency and/or clinical steatorrhea was recorded in 41% and 36% of patients, respectively. The highest IPS was reported in patients with ongoing endotherapy (166 vs 50 for patients who completed endoscopy). CONCLUSION This multicentric study on CP patients showed that current alcohol drinking and smoking are associated with pain and malnutrition. Pain scores were higher in patients with ongoing endotherapy, independently of surgery.
Collapse
Affiliation(s)
- M Fernandez
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
| | - M Arvanitakis
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - C Musala
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - J Devière
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - W Van Steenbergen
- Department of Gastroenterology and Hepatology, University of Leuven, Leuven, Belgium
| | - V Putzeys
- Department of Gastroenterology, Centre Hospitalier Régional de la Citadelle, Liège, Belgium
| | - F Ausloos
- Department of Gastroenterology, Centre Hospitalier Chrétien de Liège, Liège, Belgium
| | - B Bastens
- Department of Gastroenterology, Centre Hospitalier Chrétien de Liège, Liège, Belgium
| | - P Gast
- Department of Gastroenterology, Centre Hospitalier Universitaire du Sart-Tilman, Université de Liège, Liège, Belgium
| | - G Roeyen
- Department of Hepatobiliary, Endocrine, and Transplantation Surgery, Universitair Ziekenhuis Antwerpen, Universiteit Antwerpen, Antwerp, Belgium
| | - F Berrevoet
- Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, Ghent, Belgium
| | - I Scheers
- Pediatric Gastroenterology, Hepatology, and Nutrition Unit, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - M Delhaye
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - P H Deprez
- Department of Hepato-gastroenterology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
5
|
Cheron J, Deviere J, Ballarin A, Supiot F, Eisendrath P, Toussaint E, Huberty V, Musala C, Blero D, Lemmers A, Van Gossum A, Arvanitakis M. WITHDRAWN: The use of enteral access for continuous delivery of levodopa-carbidopa in patients with advanced Parkinson's disease. NUTR CLIN METAB 2017. [DOI: 10.1016/j.nupar.2017.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Cheron J, Deviere J, Supiot F, Ballarin A, Eisendrath P, Toussaint E, Huberty V, Musala C, Blero D, Lemmers A, Van Gossum A, Arvanitakis M. The use of enteral access for continuous delivery of levodopa-carbidopa in patients with advanced Parkinson's disease. United European Gastroenterol J 2016; 5:60-68. [PMID: 28405323 DOI: 10.1177/2050640616650804] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2016] [Accepted: 04/27/2016] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Continuous delivery to the jejunum of levodopa-carbidopa is a promising therapy in patients with advanced Parkinson's disease, as it reduces motor fluctuation. Percutaneous endoscopic gastrostomy and jejunal tube (PEG-J) placement is a suitable option for this. However, studies focused in PEG-J management are lacking. OBJECTIVES We report our experience regarding this technique, including technical success, adverse events and outcomes, in patients with advanced Parkinson's disease. METHODS Twenty-seven advanced Parkinson's disease patients (17 men, median age: 64 years, median disease duration: 11 years) were included in a retrospective study from June 2007 to April 2015. The median follow-up period was 48 months (1-96). RESULTS No adverse events were noted during and after nasojejunal tube insertion (to assess treatment efficacy). After a good therapeutic response, a PEG-J was placed successfully in all patients. The PEG tube was inserted according to Ponsky's method. The jejunal extension was inserted during the same procedure in all patients. Twelve patients (44%) experienced severe adverse events related to the PEG-J insertion, which occurred after a median follow-up of 15.5 months. Endoscopy was the main treatment modality. Patients who experienced severe adverse events had a higher comorbidity score (p = 0.011) but were not older (p = 0.941) than patients who did not. CONCLUSIONS While all patients responded well to levodopa-carbidopa regarding neurological outcomes, gastro-intestinal severe adverse events were frequent and related to comorbidities. Endoscopic treatment is the cornerstone for management of PEG-J related events. In conclusion, clinicians and endoscopists, as well as patients, should be fully informed of procedure-related adverse events and patients should be followed in centres experienced in their management.
Collapse
Affiliation(s)
- Julian Cheron
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium; Department of Neurology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Jacques Deviere
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Frederic Supiot
- Department of Neurology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Asuncion Ballarin
- Nutrition Team, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Pierre Eisendrath
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Emmanuel Toussaint
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Vincent Huberty
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Carmen Musala
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Daniel Blero
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Arnaud Lemmers
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - André Van Gossum
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium; Nutrition Team, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Marianna Arvanitakis
- Department of Gastroenterology, Hepatopancreatology and GI Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium; Nutrition Team, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
7
|
Cheron J, Deviere J, Ballarin A, Supiot F, Eisendrath P, Toussaint E, Huberty V, Musala C, Blero D, Lemmers A, Van Gossum A, Arvanitakis M. Use of enteral access for continuous delivery of levodopa-carbidopa in patients with advanced Parkinson's disease. NUTR CLIN METAB 2016. [DOI: 10.1016/j.nupar.2016.01.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Musala C, Closset J, Loi P, Coppens E, Devière J, Lemmers A. Mid-gut bleeding due to a chronic splanchnic vascular stricture with secondary portal hypertension after gastric bypass. Endoscopy 2016; 47 Suppl 1 UCTN:E83-4. [PMID: 25926227 DOI: 10.1055/s-0034-1391234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- Carmen Musala
- Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
| | - Jean Closset
- Department of Abdominal Surgery, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
| | - Patrizia Loi
- Department of Abdominal Surgery, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
| | - Emmanuel Coppens
- Department of Radiology, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
| | - Jacques Devière
- Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
| | - Arnaud Lemmers
- Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium
| |
Collapse
|
9
|
Musala C, Eisendrath P, Brasseur A, Vincent JL, Cappeliez S, Le Moine O, Devière J, Lemmers A. Successful treatment of Boerhaave syndrome with an over-the-scope clip. Endoscopy 2015; 47 Suppl 1 UCTN:E24-5. [PMID: 25603512 DOI: 10.1055/s-0034-1390718] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- Carmen Musala
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| | - Pierre Eisendrath
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| | - Alexandre Brasseur
- Department of Intensive Care, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| | - Jean-Louis Vincent
- Department of Intensive Care, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| | - Serge Cappeliez
- Department of Abdominal Surgery, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| | - Olivier Le Moine
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| | - Jacques Devière
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| | - Arnaud Lemmers
- Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, Free University of Brussels, Erasme Hospital, Brussels, Belgium
| |
Collapse
|